KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) Leases (2019 - 2025)

Novartis Ag's Leases history spans 7 years, with the latest figure at $1.4 billion for Q2 2025.

  • On a quarterly basis, Leases rose 5.7% to $1.4 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $1.4 billion, a 5.7% increase, with the full-year FY2024 number at $47.0 million, up 193.75% from a year prior.
  • Leases hit $1.4 billion in Q2 2025 for Novartis Ag, up from $47.0 million in the prior quarter.
  • Over the last five years, Leases for NVS hit a ceiling of $68.7 billion in Q2 2021 and a floor of $12.0 million in Q1 2022.
  • Historically, Leases has averaged $9.5 billion across 5 years, with a median of $133.0 million in 2023.
  • Biggest five-year swings in Leases: soared 4778.12% in 2021 and later tumbled 98.88% in 2023.
  • Tracing NVS's Leases over 5 years: stood at $1.6 billion in 2021, then fell by 8.33% to $1.4 billion in 2022, then tumbled by 98.88% to $16.0 million in 2023, then soared by 193.75% to $47.0 million in 2024, then soared by 2976.6% to $1.4 billion in 2025.
  • Business Quant data shows Leases for NVS at $1.4 billion in Q2 2025, $47.0 million in Q4 2024, and $45.0 million in Q3 2024.